BTCY - הכנסה תפעולית לפני ניכוי פחת Biotricity

Asian chip shortages and cyber threats are hindering Biotricity, Inc. (BTCY) logistics, yet the projected EBITDA level confirms business resilience, where the value captures the metric level. The asset relies on the defensive status of medical innovations that remain independent of macroeconomic trends. Strong pricing power is supported by the uniqueness of Bioflux, which provides continuous AI-driven ECG monitoring to prevent strokes.

The digitalization of cardiac monitoring via Biotricity, Inc. (BTCY) IoT platforms optimizes medical logistics, directly impacting cash flow generation. EBITDA dynamics reflect the volume of actual operating cash before debt payments and taxes, where increasing values confirm the viability of the business model, while a sharp decline indicates a risk of liquidity loss and the potential default of the issuer's capital.